Sort   by:  
 Page size 
TranscriptomicsExcessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment
Background Identification of patients at risk of tuberculosis relapse following treatment would revolutionize clinical trials of new drugs and regimens and facilitate clinical management. The study aim was to determine whether tuberculosis patients who subsequently suffer relapse have different immu...
ORGANISM(S): Homo sapiens 
2015-09-10 | E-GEOD-67589 | biostudies-arrayexpress
TranscriptomicsTuberculosis Patients Blood Gene Expression Through Treatment (cured and end-of-treatment patients)
Background Accurate assessment of treatment efficacy would facilitate clinical trials of new anti-tuberculosis drugs. TB patients exhibit altered peripheral immunity which reverts during successful treatment. We hypothesised that these changes could be observed in whole blood transcriptome profiles...
ORGANISM(S): Homo sapiens 
2012-08-09 | E-GEOD-36238 | biostudies-arrayexpress
TranscriptomicsTuberculosis patients blood gene expression through treatment
Background Accurate assessment of treatment efficacy would facilitate clinical trials of new anti-tuberculosis drugs. TB patients exhibit altered peripheral immunity which reverts during successful treatment. We hypothesised that these changes could be observed in whole blood transcriptome profiles...
ORGANISM(S): Homo sapiens 
2012-08-09 | E-GEOD-31348 | biostudies-arrayexpress
UnknownElective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.
Not available
S-EPMC8189635 | biostudies-literature
UnknownAt-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods.
Not available
S-EPMC11252333 | biostudies-literature
UnknownDevelopment and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study.
Not available
S-EPMC7832571 | biostudies-literature
UnknownSafety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Not available
S-EPMC9084623 | biostudies-literature
UnknownSafety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Not available
S-EPMC8639161 | biostudies-literature
UnknownCo-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study.
Not available
S-EPMC8172149 | biostudies-literature
UnknownSafety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Not available
S-EPMC7723445 | biostudies-literature
Sort   by:  
 Page size